Castle Biosciences reports Q4 EPS (8c), consensus (26c)

Reports Q4 revenue $87.0M, consensus $80.31M. The company said, “We exited 2025 with clear leadership across our core dermatologic and gastrointestinal franchises, highlighted by continued momentum in TissueCypher, which achieved 86% test report growth over 2024. In 2025, we also delivered an important milestone with the limited access launch of AdvanceAD-Tx(TM), which materially expanded our total addressable market and reinforced our commitment to providing clinical answers to dermatology clinicians and their patients. As we look ahead to 2026 and beyond, we believe we are well positioned to continue delivering stockholder value and capitalize on our near- and long-term opportunities, supported by continued test adoption growth for our core tests, a robust pipeline and a strong balance sheet.”